Clinical Trial Update: Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating doxorubicin hydrochloride liposome with rituximab in combination chemotherapy for newly diagnosed Burkitt's lymphoma or Burkit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Burkitt-like Lymphoma
• Lymphoma

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE)
• Rituximab (rituximab)

Snippet

Sponsor: Northwestern University | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-10-15